肿瘤突变负担对 NSCLC 中 PD-1/PD-L1 抑制剂的预测价值：一项荟萃分析。
Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis.
机构信息
Department of Respiratory and Critical Care Medicine, Xi'an Chest Hospital, Chang'an District, Xi'an, Shanxi, China.
出版信息
Medicine (Baltimore). 2023 Oct 6;102(40):e34990. doi: 10.1097/MD.0000000000034990.
BACKGROUND
To investigate the association between tumor mutational burden (TMB) and the therapeutic effect of Programmed Death 1/Programmed Death Ligand 1 inhibitors in non-small cell lung cancer.
METHODS
Four electronic databases, PubMed, Embase, Web of Science, and Cochrane Library, were searched on May 10, 2023, and no time limitation was applied. Analyses were performed using STATA17.0. We assessed the methodological quality of each randomized controlled trial using the Newcastle-Ottawa scale.
RESULTS
After exhaustive database search and rigorous screening, 10 studies were included in the meta-analysis. Our findings indicate that high TMB significantly improves progression-free survival but reduces overall response rate. The overall survival was not significantly different between the high and low TMB groups. No significant publication bias was observed.
CONCLUSION
High TMB serves as a potential predictive biomarker for improved progression-free survival and reduced overall response rate in patients with non-small cell lung cancer treated with programmed death 1/programmed death ligand 1 inhibitors. However, its predictive value in overall survival requires further investigation.
背景
探讨肿瘤突变负担（TMB）与程序性死亡受体 1/程序性死亡配体 1 抑制剂在非小细胞肺癌中的治疗效果之间的关联。
方法
于 2023 年 5 月 10 日检索了 PubMed、Embase、Web of Science 和 Cochrane Library 这四个电子数据库，未设置时间限制。使用 STATA17.0 进行分析。我们使用纽卡斯尔-渥太华量表评估了每个随机对照试验的方法学质量。
结果
经过彻底的数据库搜索和严格筛选，共有 10 项研究纳入荟萃分析。我们的研究结果表明，高 TMB 显著改善了无进展生存期，但降低了总体缓解率。高 TMB 组和低 TMB 组之间的总生存期无显著差异。未观察到明显的发表偏倚。
结论
高 TMB 可作为预测标志物，用于预测程序性死亡受体 1/程序性死亡配体 1 抑制剂治疗的非小细胞肺癌患者的无进展生存期延长和总体缓解率降低。然而，其在总生存期方面的预测价值尚需进一步研究。
Zotero 插件